Accelerated Pharma (Accelerated Pharma) Net Margin % : 0.00% (As of Mar. 2017)

View and export this data going back to 2016. Start your Free Trial

What is Accelerated Pharma Net Margin %?

Net margin is calculated as Net Income divided by its Revenue. Accelerated Pharma's Net Income for the three months ended in Mar. 2017 was $-0.64 Mil. Accelerated Pharma's Revenue for the three months ended in Mar. 2017 was $0.00 Mil. Therefore, Accelerated Pharma's net margin for the quarter that ended in Mar. 2017 was 0.00%.

The historical rank and industry rank for Accelerated Pharma's Net Margin % or its related term are showing as below:

ACCP's Net Margin % is not ranked ^*
in the Drug Manufacturers industry.
Industry Median: 3.53
* Ranked among companies with meaningful Net Margin % only.

Accelerated Pharma Net Margin % Historical Data

The historical data trend for Accelerated Pharma's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Accelerated Pharma Net Margin % Chart

Accelerated Pharma Annual Data

Trend

Dec14

Dec15

Dec16

Net Margin %

Accelerated Pharma Quarterly Data
	Jun15	Sep15	Dec15	Mar16	Jun16	Sep16	Dec16	Mar17
Net Margin %	Get a 7-Day Free Trial			-	-	-	-	-

Competitive Comparison of Accelerated Pharma's Net Margin %

For the Drug Manufacturers - Specialty & Generic subindustry, Accelerated Pharma's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Accelerated Pharma's Net Margin % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Accelerated Pharma's Net Margin % distribution charts can be found below:

* The bar in red indicates where Accelerated Pharma's Net Margin % falls into.

Accelerated Pharma Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

Accelerated Pharma's Net Margin for the fiscal year that ended in Dec. 2016 is calculated as

Net Margin	=	Net Income (A: Dec. 2016 )	/	Revenue (A: Dec. 2016 )
	=	-3.93	/	0
	=	%

Accelerated Pharma's Net Margin for the quarter that ended in Mar. 2017 is calculated as

Net Margin	=	Net Income (Q: Mar. 2017 )	/	Revenue (Q: Mar. 2017 )
	=	-0.636	/	0
	=	%

Accelerated Pharma (NAS:ACCP) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.

Accelerated Pharma Net Margin % Related Terms

Thank you for viewing the detailed overview of Accelerated Pharma's Net Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Accelerated Pharma (Accelerated Pharma) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Accelerated Pharma Inc (NAS:ACCP) » Definitions » Net Margin %

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

Accelerated Pharma Inc, is a Delaware corporation organized on May 12, 2014. It is a biopharmaceutical company focused on utilizing its genomic technology to enhance the development and commercialization of pharmaceutical products. Its lead product candidate is Picoplatin, a new generation platinum-based cancer therapy that has the potential for use in different formulations, as a single agent or in combination with other anti-cancer agents, to treat multiple cancer indications.

Accelerated Pharma (Accelerated Pharma) Headlines

No Headlines